Wani zaɓi na Jiyya
Akwai hanyoyi masu yawa na zafin jiki don mutanen dake da psoriasis masu tsaka-tsakin zuciya ko kuma cututtuka na psoriatic. Ɗaya daga cikin maƙalar da ake amfani dasu shine magani leflunomide. Zai iya zama mahimmanci a gare ku idan cutar ba ta amsawa sosai ba, ko kuma idan baza ku iya ɗaukar wasu jiyya ba.
Mene ne Leflunomide?
Leflunomide (sunan kasuwanci Arava) wani maganin maganin maganin daji ne wanda za a iya amfani dasu don biyan cututtuka na psoriatic da matsananciyar cutar psoriasis.
Sunan sunadarai sunada N- (4'-trifluoromethylphenyl) -5-methylisoxazole-4-carboxamide.
FDA dai ta amince da leflunomide don maganin cututtuka na rheumatoid. Da'awar magana, FDA ba ta amince da ita ba don magance psoriasis da kuma cututtuka na psoriatic arthritis - ba a yi gwajin gwagwarmaya ba. Duk da haka, duka psoriasis da rheumatoid arthritis sune yanayi maras ƙura wanda zai iya shafar dakunan, kuma suna rabawa wasu matakai na aikin likita. Wasu nazarin binciken likita suna nuna cewa leflunomide yana da tasiri a wajen magance cututtukan fata a psoriasis da kuma fata da haɗin gwiwa a cikin mutanen da ke dauke da cututtuka. Don haka likitoci a wani lokacin sun rubuta maganin "lakabi".
Leflunomide yana daya daga cikin tsoffin maganin gargajiya da za a iya amfani dasu don magance matsananciyar cutar psoriasis da psthritic arthritis. Wannan yana sanya shi a cikin rukuni tare da methotrexate, cyclosporine, da sauran kwayoyi.
Duk da haka, ba a yi amfani da leflunomide kamar sauran kwayoyi ba. Kuna iya ji wadannan kwayoyi da ake kira DMARDs ko maganin cututtukan maganin antirheumatic. Kamar wadannan kwayoyi, leflunomide ba daya daga cikin sababbin kwayoyin "kwayoyin halitta" da aka yi daga sunadaran mutum ko dabba.
Yaya Yada Ayyukan Leflunomide?
Aikin Leflunomide ba shi da cikakken sani.
Duk da haka, yana nuna aiki a kalla a wani ɓangare ta hanyar hana wani enzyme da ake buƙata don ƙirƙirar sabon DNA (abin da ka gaji). Lokacin da kumburi ya auku, jikinka yana sa sababbin kwayoyin cutar kumburi. Ta hanyar rage jinkirin DNA kira, leflunomide zai iya toshe wasu daga cikin kumburi da ke haifar da bayyanar cututtuka na psoriasis da rubutun cututtuka na psoriatic. Duk da haka, saboda yana rufe tsarin rigakafi, zai iya samun wasu tasiri.
Ta yaya zan ɗauki Leflunomide?
Yi amfani da abinci tare da abinci, kamar yadda likitancin ya umarta. Ana samun miyagun ƙwayoyi a 10mg, 20mg, da 100mg siffofin. Lokacin da kuka fara fara magani, likita zai iya ba ku girma fiye da al'ada, wanda ake kira "nau'in nau'i" (yawanci 100mg na kwana uku). Bayan matakin miyagun ƙwayoyi ya tashi a cikin jikinka, zaka dauki nauyin tabbatarwa (yawanci 20mg kowace rana).
Wanda Ya Amfana Daga Leflunomide?
Akwai wasu maganganun gargajiya na gargajiya don bi da psoriasis, kamar methotrexate. Sauran sababbin kwayoyin "kwayoyin halitta " kamar Enbrel (kwatsam) suna samuwa. Doctors yawanci kawai rubũta leflunomide bayan wasu zažužžukan kulawa ba su ci nasara. Duk da haka, dole ne a dauki sababbin kwayoyin halittu ta hanyar kwayar halitta, kuma sun fi tsada fiye da jiyya marasa lafiya.
Idan wani magungunan ƙwayar magunguna ba ya aiki a gare ku ba, kuna iya gwada leflunomide kafin ku koma magani. A wasu lokuta, likitanku zai iya rubuta leflunomide banda wani magani na maganganu, kamar hanya.
Mutane tare da m psoriasis ya kamata su yi amfani da jiyya na asali kuma ba kwayoyi magunguna kamar leflunomide.
Matsaloli na Yanayi na Leflunomide
Wasu daga cikin sakamakon da leflunomide mafi rinjaye na yau da kullum ya haifar da hangen nesa na tsarin gastrointestinal. Alal misali, waɗannan zasu haɗa da:
- Diarrhea (mafi yawan na kowa)
- Jiɗa
- Upset ciki
Sauran cututtuka masu illa sun haɗa da:
- Rash (da wuya mai tsanani)
- Asarar gashi
- Haɗakar hanta enzymes (nuna hasara hanta)
- Ƙarin haɗarin kamuwa da cuta
- Raguwar jini ko plalets (daga rage yawan kayan aiki a cikin kututtukan kasusuwa)
Sauran cututtuka masu illa sune:
- Fashin fibrosis
- Pain tare da urination
- Magungunan rashin lafiyar jiki kamar cututtuka ko rashin hankali
Bincike da gwajin Laboratory yayin da yake daukar Leflunomide
Kafin fara leflunomide, likitanku zai dauki tarihin lafiyarku kuma ya yi nazari na jiki. Wannan yana taimaka wa likitan ku tabbatar cewa babu wata dalili da cewa leflunomide zai zama mummunan zabi a gareku. Tabbatar gaya wa likitan ku game da dukkan magunguna da kuke ɗauka, ciki har da magungunan ƙwayoyin magunguna. Wadannan zasu iya tasiri tasiri na leflunomide da kuma hadarin da zai yiwu.
Saboda hadarin wadansu cututtukan kwayoyi, masu shan leflunomide suna buƙatar wasu gwaje-gwaje na gwaje-gwaje na yau da kullum. Kuna buƙatar waɗannan kafin fara farawa sannan sannan a lokaci na lokaci. Alal misali, ƙila ka buƙaci gwaje-gwaje masu zuwa:
- Kammala ƙimar jini (don saka idanu da jinin jinin ku, kwayoyin jinin jini, da plalets)
- Gwaran gwaje-gwaje, irin su ALT
Mutanen da ke shan leflunomide ma sun buƙaci gwadawa ta farko don tabbatar da cewa basu da wani hali na tayi akan tarin fuka. (Drugs kamar leflunomide zai iya sa cutar ya fi aiki.)
Magunguna da Leflunomide
Mutane shan leflunomide ba su da wasu irin maganin alurar da ke dauke da wani ɓangare na cutar mai rai. Wannan ba yana nufin kada ku dauki dukkan maganin alurar rigakafi-kawai ku tambayi likitanku na farko. Kuna so in sami wasu maganin alurar (kamar tetanus booster ) kafin ka fara shan leflunomide.
Wanda ba zai iya ɗaukar Leflunomide ba?
Bai kamata ka dauki leflunomide ba idan kana da rashin lafiya da aka sani game da miyagun ƙwayoyi ko ɗaya daga cikin abubuwan da aka gyara. Haka kuma kada ku dauki leflunomide idan tsarinku na rigakafi ya dace da wani daga cikin wadannan:
- Kyakkyawan cutar rashin lafiya
- Matsalolin da ke gudana tare da kututtukan ka
- Wani mummunar cuta mai tsanani, wanda ba shi da kariya
Mace masu ciki kuma kada su dauki leflunomide.
Yara da Yarda da Yara da Leflunomide
Leflunomide wani nau'i ne na X a lokacin daukar ciki, wanda ke nufin cewa hatsarin da aka sani na miyagun ƙwayoyi ya fi ƙarfin amfaninta. Ana tsammanin zai kara yawan haɗarin mutuwar tayi da kuma lahani na haihuwa. Duk mata masu tayar da hankali suna bukatar suyi jarrabawar ciki kafin su fara magani. Ya kamata ku ci gaba da yin amfani da maganin rigakafi da aka dogara a duk tsawon lokacin da kuka ɗauki leflunomide.
Idan kuna shan leflunomide kuma kuyi ciki, sai ku kira likitan likitanku nan da nan ku gaya musu halinku. Kwararka zai iya ba da shawara game da yiwuwar hadarin ka zuwa ciki. Kwararka zai iya yin bayani cewa likita yana jiyya (wanda ake kira cholestyramine) wanda zai iya rage yawan leflunomide. Wannan yana rage hadarin cutar ga tayin.
Idan kuna shan da leflunomide kuma kuna so kuyi juna biyu, ku yi magana da likitan ku kafin ku fara kokarin gwadawa. An ba da shawarar cewa duk mata masu tsufa da haihuwa ta hanyar yin amfani da miyagun ƙwayoyi ba su kai ga rage yawan leflunomide ba. Wannan yana da mahimmanci ga matan da ke ƙoƙari suyi tunani. Ba tare da yin wannan mataki ba, zai yiwu har zuwa shekaru biyu don leflunomide ya fada cikin matakan tsaro ga tayi a jikinka. Mata kada kuma su dauki leflunomide yayin da ake shayarwa.
Masana kimiyya sun yi imanin cewa leflunomide bazai kara yawan hadarin haihuwa na haihuwa ba ga maza da ke haifa yara. Duk da haka, ba a aiwatar da waɗannan nazarin dabba ba. Don kauce wa kowane haɗari, mutane ya kamata su daina ɗaukar miyagun ƙwayoyi kafin kokarin ƙoƙari suyi juna da abokin tarayya. Tabbatacce ya kamata su shiga ta hanyar maganin miyagun ƙwayoyi ne.
Kalma Daga
Abin farin, akwai yanzu zaɓuɓɓukan zaɓuɓɓuka don mutanen da ke fama da matsananciyar cutar psoriasis ko psritic arthritis. Leflunomide na iya zama wani zaɓi don la'akari da abin da kuka yi kokarin bai dace da lafiyar ku ba.
> Sources:
> Arava. Bayyana Bayani . Bridgewater, NJ: Sanofi-Aventis; 2010.
> Leflunomide (Arava). Kwalejin Amirka na Rheumatology. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Leflunomide-Arava. Updated Maris 2017.
> Menter A, Korman NJ, Elmets CA, et al. Sharuɗɗa na kulawa da gudanar da psoriasis da psthritic arthritis: sashi na 4. Sharuɗɗa na kula da gudanarwa da kuma kula da psoriasis tare da masu amfani da kayan gargajiya. J Am Acad Dermatol . 2009; 61 (3): 451-85. Doi: 10.1016 / j.jaad.2009.03.027.